Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women?

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 430-436

  Acosta, Edward P ^a   Bardeguez, Arlene ^b   Zorrilla, Carmen D ^c   Van Dyke, Russell ^e   Hughes, Michael D ^f   Huang, Sharon ^f   Pompeo, Lisa ^b   Stek, Alice M ^g   Pitt, Jane ^h   Watts, D Heather ⁱ   Smith, Elizabeth ^j   Jiménez, Eleanor ^d   Mofenson, Lynne ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d San Juan City Hospital   (Puerto Rico)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; DELIVERY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMBINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR; LOW DRUG DOSE; MATERNAL DISEASE; METABOLISM; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DELIVERY, OBSTETRIC; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; LABOR, OBSTETRIC; POSTPARTUM PERIOD; PREGNANCY; RITONAVIR; RNA, VIRAL; SAQUINAVIR;

EID: 9144268274     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.430-436.2004     Document Type: Article

References (13)

1. Acosta, E. P., T. N. Kakuda, R. C. Brundage, P. L. Anderson, and C. V. Fletcher. 2000. Pharmacodynamics of HIV-1 protease inhibitors. Clin. Infect. Dis. 30(Suppl. 2):S151-S159.
2. Acosta, E. P., C. D. Zorrilla, R. Van Dyke, A. Bardeguez, B. Smith, M. Hughes, J. Pitt, H. Watts, L. Mofenson, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. 2001. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin. Trials 2:460-465.
3. Acosta, E. P., J. G. Gerber, and the Adult ACTG Pharmacology Committee. 2002. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res. Hum. Retrovir. 18:825-834.
4. Audus, K. L., M. L. Soares, and J. S. Hunt. 2002. Characteristics of the fetal/maternal interface with potential usefulness in the development of future immunological and pharmacological strategies. J. Pharmacol. Exp. Ther. 301:402-409.
5. Condra, J. H., C. J. Petropoulus, R. Ziermann, W. A. Schleif, M. Shivaprakash, and E. A. Emini. 2000. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182:758-765.
6. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
7. Gieschke, R., B. Fotteler, N. Buss, and J.-L. Steimer. 1999. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin. Pharmacokinet. 37:75-86.
8. Lalezari, J. 1998. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19:195-196.
9. Little, B. B. 1999. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet. Gynecol. 93:858-808.
10. Loebstein, R., A. Lalkin, and G. Koren. 1997. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin. Pharmacokinet. 33:328-343.
11. Turner, M. L., K. Reed-Walker, J. R. King, and E. P. Acosta. 2003. Simultaneous quantitation of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma using a single high-performance liquid chromatography methodology. J. Chromatogr. B 784:331-341.
12. Veldkamp, A. I., R. P. G. van Heeswijk, J. W. Mulder, P. L. Meenhorst, G. Schreij, S. van der Geest, J. M. A. Lange, J. H. Beijnen, and R. M. W. Huetelmans. 2001. Steady-state pharmacokinetics of twice daily dosing of saquinavir plus ritonavir in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 27:344-349.
13. Washington, C. B., G. E. Duran, M. C. Man, B. I. Sikic, and T. F. Blaschke. 1998. Interaction of anti-HIV protease inhibitors with the multidrug transporter p-glycoprotein (P-gp) in human cultured cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19:203-209.